Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director | January 02, 2026 | January 06, 2026 |
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Director | August 03, 2026 | August 06, 2026 |
| Spero Therapeutics, Inc.SPRO · Entity 7014 | Director | June 05, 2018 | June 07, 2018 |
| TScan Therapeutics, Inc.TCRX · Entity 7255 | Director · Chief Executive Officer | February 02, 2023 | February 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,850 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 4,000 · Balance 20,850 F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.74 · Expires 2036-01-01 | Direct | 3,475 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 3,475 · Balance 3,475 F2: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death.
F2: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.
ROCKET PHARMACEUTICALS, INC.
Report date August 03, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 204,522 |
Reported balance
After 2026-08-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-03 · Other · Acquired 150,000 · Balance 204,522 F1: Rocket Pharmaceuticals, Inc. (the "Company") entered into a consulting agreement with the Reporting Person, dated July 21, 2026, for consulting services related to the Company's strategic and financial activities. As compensation for services rendered, the Reporting Person received 150,000 restricted stock units ("RSUs") on August 3, 2026. F2: Represents RSUs that convert to common stock on a one-for-one basis. One-third of such RSUs will vest in full on August 3, 2027, with the remaining two-thirds vesting in equal quarterly installments over the following two years. |
| Common StockSEC Table I · non-derivative | IndirectBy The David P. Southwell Irrevocable Trust Dtd 04/14/2024 | 113,124 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 113,124 |
Filing footnotes · ownership attribution and instrument terms
F1: Rocket Pharmaceuticals, Inc. (the "Company") entered into a consulting agreement with the Reporting Person, dated July 21, 2026, for consulting services related to the Company's strategic and financial activities. As compensation for services rendered, the Reporting Person received 150,000 restricted stock units ("RSUs") on August 3, 2026.
F2: Represents RSUs that convert to common stock on a one-for-one basis. One-third of such RSUs will vest in full on August 3, 2027, with the remaining two-thirds vesting in equal quarterly installments over the following two years.
Spero Therapeutics, Inc.
Report date June 05, 2018 · Filed June 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.54 · Expires 2028-06-05 | Direct | 6,073 |
Reported balance
After 2018-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-05 · Grant · Acquired 6,073 · Balance 6,073 F1: The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date.
TScan Therapeutics, Inc.
Report date February 02, 2023 · Filed February 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.81 · Expires 2033-02-01 | Direct | 100,000 |
Reported balance
After 2023-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-02 · Grant · Acquired 100,000 · Balance 100,000 F1: The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 6, 2026 00:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-031471 · form4.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,522 F1 · security: Rocket Pharmaceuticals, Inc. (the "Company") entered into a consulting agreement with the Reporting Person, dated July 21, 2026, for consulting services related to the Company's strategic and financial activities. As compensation for services rendered, the Reporting Person received 150,000 restricted stock units ("RSUs") on August 3, 2026. F1 · kind: Rocket Pharmaceuticals, Inc. (the "Company") entered into a consulting agreement with the Reporting Person, dated July 21, 2026, for consulting services related to the Company's strategic and financial activities. As compensation for services rendered, the Reporting Person received 150,000 restricted stock units ("RSUs") on August 3, 2026. F2 · price: Represents RSUs that convert to common stock on a one-for-one basis. One-third of such RSUs will vest in full on August 3, 2027, with the remaining two-thirds vesting in equal quarterly installments over the following two years. Read SEC document |
| June 18, 2026 Filed Jul 6, 2026 23:59 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 64,860 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001140361-26-027677 · form4.xml · derivative · entry 3 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,860 Underlying: Common Stock · 64,860 shares Expires 2036-06-18 F2 · derivative.exercise_date: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jul 6, 2026 23:59 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 22,862 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-027677 · form4.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,522 F1 · security: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. F1 · price: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 3,475 | $0.00 Strike: $76.74 | $0.00 |
DisclosureSEC source: 0001251553-26-000002 · form4-01062026_050112.xml · derivative · entry 2 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,475 Underlying: Common Stock · 3,475 shares Expires 2036-01-01 F2 · derivative.exercise_date: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001251553-26-000002 · form4-01062026_050112.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,850 F1 · shares: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $30.86 | $0.00 |
DisclosureSEC source: 0001415889-25-024280 · form4-09112025_040902.xml · derivative · entry 3 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 12,000 | $58.34 | $700,080.00 |
DisclosureSEC source: 0001415889-25-024280 · form4-09112025_040902.xml · nonDerivative · entry 2 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,850 F1 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $58.31 to $58.45 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 12,000 | $30.86 | $370,320.00 |
DisclosureSEC source: 0001415889-25-024280 · form4-09112025_040902.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jul 18, 2025 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-026404 · form4.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,660 F1 · security: Represent restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. F1 · price: Represent restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 8,800 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001415889-25-001027 · form4-01072025_050126.xml · derivative · entry 3 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 8,800 shares Expires 2035-01-02 F2 · derivative.exercise_date: This option was granted on January 3, 2025 and vests over one year in twelve equal monthly installments, commencing on February 3, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001027 · form4-01072025_050126.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,850 F1 · shares: Restricted stock units granted on January 3, 2025 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 17, 2025 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 3, 2026. Read SEC document |
| June 13, 2024 Filed Jun 20, 2024 20:10 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 23,944 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001140361-24-030728 · form4.xml · derivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,944 Underlying: Common Stock · 23,944 shares Expires 2034-06-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 23,944 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025. Read SEC document |
| May 08, 2024 Filed May 10, 2024 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GiftCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012891 · form4-05102024_050502.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,850 F1 · kind: Represents the transfer of shares by the Reporting Person to The David P. Southwell Irrevocable Trust of 2024 (the "Trust") for no consideration. The Trust has an independent trustee with investment control over the transferred shares, and the Reporting Person and members of his family are the beneficiaries of the Trust. Read SEC document |
| May 02, 2024 Filed May 20, 2024 20:39 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GiftCommon Stock | 59,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026884 · form4.xml · nonDerivative · entry 2 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The David P. Southwell Irrevocable Trust Dtd 04/14/2024 Disclosed balance after: 113,124 F1 · price: The shares of common stock were transferred by the Reporting Person as a gift to The David P. Southwell Irrevocable Trust Dtd 04/14/2024. No funds were exchanged, and no sale of shares occurred in the transfer. Read SEC document |
| May 02, 2024 Filed May 20, 2024 20:39 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GiftCommon Stock | 113,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026884 · form4.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,660 F1 · price: The shares of common stock were transferred by the Reporting Person as a gift to The David P. Southwell Irrevocable Trust Dtd 04/14/2024. No funds were exchanged, and no sale of shares occurred in the transfer. Read SEC document |
| April 15, 2024 Filed Apr 16, 2024 21:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionStock Option (Right to Buy) · Derivative | 29,624 | $4.34 Strike: $4.34 | $128,627.41 |
DisclosureSEC source: 0001140361-24-020127 · form4.xml · derivative · entry 7 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,624 shares Expires 2024-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option represents a right to purchase a total of 99,624 shares of the Issuer's Common Stock, which became fully vested and exercisable on January 4, 2018. Read SEC document |
| April 15, 2024 Filed Apr 16, 2024 21:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 10,000 | $24.05 | $240,520.00 |
DisclosureSEC source: 0001140361-24-020127 · form4.xml · nonDerivative · entry 5 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,784 F4 · security: Shares were sold by the Reporting Person in order to cover certain tax obligations. F5 · price: Represents a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.85 to $24.335. The Reporting Person has provided the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 15, 2024 Filed Apr 16, 2024 21:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 29,624 | $4.34 | $128,627.41 |
DisclosureSEC source: 0001140361-24-020127 · form4.xml · nonDerivative · entry 4 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares received upon exercise of Stock Options, which would otherwise expire in August 2024. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 21:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionStock Option (Right to Buy) · Derivative | 70,000 | $4.34 Strike: $4.34 | $303,940.00 |
DisclosureSEC source: 0001140361-24-020127 · form4.xml · derivative · entry 6 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,624 Underlying: Common Stock · 70,000 shares Expires 2024-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option represents a right to purchase a total of 99,624 shares of the Issuer's Common Stock, which became fully vested and exercisable on January 4, 2018. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 21:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 10,284 | $25.16 | $258,704.30 |
DisclosureSEC source: 0001140361-24-020127 · form4.xml · nonDerivative · entry 3 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,160 F4 · security: Shares were sold by the Reporting Person in order to cover certain tax obligations. F3 · price: Represents a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.155 to $25.17. The Reporting Person has provided the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 21:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 59,716 | $24.22 | $1,446,560.38 |
DisclosureSEC source: 0001140361-24-020127 · form4.xml · nonDerivative · entry 2 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,444 F4 · security: Shares were sold by the Reporting Person in order to cover certain tax obligations. F2 · price: Represents a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.87 to $24.68. The Reporting Person has provided the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 21:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 70,000 | $4.34 | $303,940.00 |
DisclosureSEC source: 0001140361-24-020127 · form4.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares received upon exercise of Stock Options, which would otherwise expire in August 2024. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-24-004121 · form4-02162024_040201.xml · derivative · entry 2 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-02-14 F2 · derivative.exercise_date: This option was granted on February 15, 2024 and vests over one year in twelve equal monthly installments, commencing on March 15, 2024. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004121 · form4-02162024_040201.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,500 F1 · shares: Restricted stock units granted on February 15, 2024 that vest over one year, with one-third (1/3) of the shares underlying the RSUs vesting on June 18, 2024 and the remaining two-thirds (2/3) of the original shares underlying the RSUs vesting on February 15, 2025. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 23:47 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 25,850 | $0.00 Strike: $21.56 | $0.00 |
DisclosureSEC source: 0001140361-23-031525 · form4.xml · derivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,850 Underlying: Common Stock · 25,850 shares Expires 2033-06-22 F1 · derivative.exercise_date: This option represents a right to purchase a total of 25,850 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 22, 2024. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 20:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,429 | $18.01 Strike: $18.01 | $205,836.29 |
DisclosureSEC source: 0001415889-23-006696 · form4-04192023_080416.xml · derivative · entry 4 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,429 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F4 · derivative.exercise_date: Currently exercisable. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 20:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 5,188 | $51.43 | $266,839.59 |
DisclosureSEC source: 0001415889-23-006696 · form4-04192023_080416.xml · nonDerivative · entry 3 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,500 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.01 to $51.835 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 20:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 6,241 | $50.69 | $316,347.55 |
DisclosureSEC source: 0001415889-23-006696 · form4-04192023_080416.xml · nonDerivative · entry 2 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,688 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to $50.97 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 20:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 11,429 | $18.01 | $205,836.29 |
DisclosureSEC source: 0001415889-23-006696 · form4-04192023_080416.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:07 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,571 | $18.01 Strike: $18.01 | $46,303.71 |
DisclosureSEC source: 0001415889-23-005991 · form4-04042023_080442.xml · derivative · entry 3 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,429 Underlying: Common Stock · 2,571 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:07 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,571 | $50.05 | $128,672.38 |
DisclosureSEC source: 0001415889-23-005991 · form4-04042023_080442.xml · nonDerivative · entry 2 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,500 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to $50.17 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:07 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,571 | $18.01 | $46,303.71 |
DisclosureSEC source: 0001415889-23-005991 · form4-04042023_080442.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $27.05 Strike: $27.05 | $270,500.00 |
DisclosureSEC source: 0001415889-23-005565 · form4-03292023_080327.xml · derivative · entry 5 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F4 · derivative.exercise_date: Currently exercisable. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 100 | $46.03 | $4,603.00 |
DisclosureSEC source: 0001415889-23-005565 · form4-03292023_080327.xml · nonDerivative · entry 4 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,500 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 5,301 | $45.41 | $240,735.37 |
DisclosureSEC source: 0001415889-23-005565 · form4-03292023_080327.xml · nonDerivative · entry 3 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,600 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.00 to $45.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,599 | $44.71 | $205,617.61 |
DisclosureSEC source: 0001415889-23-005565 · form4-03292023_080327.xml · nonDerivative · entry 2 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $43.97 to $44.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 10,000 | $27.05 | $270,500.00 |
DisclosureSEC source: 0001415889-23-005565 · form4-03292023_080327.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 22:18 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-23-004063 · doc4.xml · derivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Voting Common Stock · 100,000 shares Expires 2033-02-01 F1 · derivative.exercise_date: The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001415889-23-000669 · form4-01092023_090110.xml · derivative · entry 2 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-01-04 F2 · derivative.exercise_date: This option was granted on January 5, 2023 and vests over one year in twelve equal monthly installments, commencing on February 5, 2023. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000669 · form4-01092023_090110.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · shares: Restricted stock units granted on January 5, 2023 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 6, 2023 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 5, 2024. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 20:30 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0000899243-22-026849 · doc4.xml · derivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Voting Common Stock · 100,000 shares Expires 2032-07-24 F1 · derivative.exercise_date: The shares subject to this option vest over 4 years of service following July 25, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. Read SEC document |
| June 13, 2022 Filed Jun 16, 2022 01:07 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 47,745 | $0.00 Strike: $10.77 | $0.00 |
DisclosureSEC source: 0001140361-22-023146 · form4.xml · derivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,745 Underlying: Common Stock · 47,745 shares Expires 2032-06-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 47,745 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2023. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:15 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | PurchaseVoting Common Stock | 10,000 | $3.55 | $35,482.00 |
DisclosureSEC source: 0000899243-22-019018 · doc4.xml · nonDerivative · entry 2 SOUTHWELL DAVID P · CIK 0001251553 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,569 F2 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $3.45 to $3.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:15 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | PurchaseVoting Common Stock | 15,000 | $3.62 | $54,339.00 |
DisclosureSEC source: 0000899243-22-019018 · doc4.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,569 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $3.379 to $3.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:25 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0000899243-22-002647 · doc4.xml · derivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Voting Common Stock · 275,000 shares Expires 2032-01-17 F1 · derivative.exercise_date: The shares subject to this option vest over 4 years of service following January 18, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 12,000 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001179110-22-000384 · edgar.xml · derivative · entry 2 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-01-06 F2 · derivative.exercise_date: This option was granted on January 7, 2022 and vests over one year in twelve equal monthly installments, commencing on February 7, 2022. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000384 · edgar.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 F1 · shares: Restricted stock units granted on January 7, 2022 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2022 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 7, 2023. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| December 23, 2021 Filed Dec 27, 2021 21:30 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | Exercise / conversionStock Option (Right to Buy) · Derivative | 48,670 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0000899243-21-049764 · doc4.xml · derivative · entry 2 SOUTHWELL DAVID P · CIK 0001251553 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,161 Underlying: Voting Common Stock · 48,670 shares Expires 2029-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares originally subject to this option vested over 4 years of service following October 9, 2018, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. In addition, all of the shares subject to this option shall vest and become fully exercisable upon a Change of Control (as defined in the option agreement). Read SEC document |
| December 23, 2021 Filed Dec 27, 2021 21:30 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | Exercise / conversionVoting Common Stock | 48,670 | $1.97 | $95,879.90 |
DisclosureSEC source: 0000899243-21-049764 · doc4.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 20:43 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | PurchaseVoting Common Stock | 11,000 | $8.73 | $96,066.30 |
DisclosureSEC source: 0000899243-21-035442 · doc4.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,899 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $8.64 to $8.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.